Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients.
Adult
Aged
Diabetes Mellitus, Type 2
/ drug therapy
Female
Glucagon-Like Peptides
/ analogs & derivatives
Glycated Hemoglobin
/ metabolism
Graft Rejection
/ prevention & control
Graft Survival
Heart Transplantation
Humans
Hypoglycemic Agents
/ therapeutic use
Immunoglobulin Fc Fragments
/ therapeutic use
Immunosuppressive Agents
/ therapeutic use
Incretins
/ therapeutic use
Insulin
/ therapeutic use
Kidney Transplantation
Liver Transplantation
Male
Middle Aged
Organ Transplantation
Recombinant Fusion Proteins
/ therapeutic use
Retrospective Studies
Transplant Recipients
GLP-1 receptor agonist
dulaglutide
post-transplant diabetes mellitus
solid organ transplantation
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
09
10
2018
revised:
06
12
2018
accepted:
07
12
2018
pubmed:
20
12
2018
medline:
8
9
2020
entrez:
20
12
2018
Statut:
ppublish
Résumé
Published data regarding the approach to management of diabetes mellitus in solid organ transplant (SOT) recipients are limited. We performed a retrospective chart review of SOT recipients with diabetes, above 18 years of age, who were usisng dulaglutide. There was a sustained, statistically significant reduction in the primary endpoints of weight, body mass index (BMI) and insulin requirement in 63 SOT recipients at 6, 12 and 24 months, respectively. A total of 59, 50 and 13 recipients were followed during 6, 12 and 24 months, with a mean paired difference for weight reduction of 2.07 (P value <0.003), 4.007 (P value <0.001) and 5.23 (P value <0.034) kgs and a BMI reduction of 0.80 (P value <0.001), 1.35 (P value <0.005) and 2.015 (P value <0.045) kg/m
Substances chimiques
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Immunoglobulin Fc Fragments
0
Immunosuppressive Agents
0
Incretins
0
Insulin
0
Recombinant Fusion Proteins
0
hemoglobin A1c protein, human
0
Glucagon-Like Peptides
62340-29-8
dulaglutide
WTT295HSY5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061-1065Informations de copyright
© 2018 John Wiley & Sons Ltd.
Références
American Diabetes Association. Standards of medical care in Diabetes 2011. Diabetes Care. 2011;34(suppl):S11.
Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care. 2010;16(suppl):S187-S194.
Sadhu AR, Schwartz SS, Herman ME. The rationale for the use of incretins in the management of new-onset diabetes after transplantation (NODAT). Endocr Pract. 2015;21:814-822.
Cariou B, Bernard C, Cantarovich D. Liraglutide in whole-pancreas transplant patients with impaired glucose homeostasis: a case series. Diabetes Metab. 2015;41:252-257.
Liou JH, Liu YM, Chen CH. Management of diabetes mellitus with glucagon-like peptide-1 agonist liraglutide in renal transplant recipients: a retrospective study. Transplant Proc. 2018;50:2502-2505.
Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care. 2013;36:e171-e172.
Barbara K, Keith C. Information for health care professionals, switching between insulin products in disaster response situations. https://www.diabetesdisasterresponse.org/. Accessed December, 5, 2018.
Grunberger G, Chang A, Soria GG, et al. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29:1260-1267.
Bisgaard LS, Bosteen MH, Fink LN, et al. Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr-/- mice. PLoS ONE. 2016;11:e0168396.
Chen P, Shi X, Xu X, et al. Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in type 2 diabetic kidney disease rat model. Diabetes Res Clin Pract. 2018;137:173-182.
Guo H, Li H, Wang B, Ding W, Ling L. Protective effects of glucagon-like peptide-1 analog on renal tubular injury in mice on high-fat diet. Cell Physiol Biochem. 2017;41:1113-1124.
Álvarez-Villalobos NA, Treviño-Alvarez AM, González-González JG. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375:1797-1798.
Røder ME. Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. Ther Adv Chronic Dis. 2018;9:33-50.
Smith LL, Mosley JF, II CP, Brown J, Barris LS, Phan LD. Dulaglutide (trulicity): the third once-weekly GLP-1 agonist. Pharm Ther. 2016;41:357
Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in Type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168-2176.